Research: 2020–present

💊 = pharma ties / conflict of interest      🐀 = animal study      🧬 = genetics focus      📚 = systematic review / meta-analysis

All periods: 2020–present | 2015–2019 | 2010–2014 | 2000–2009 | 1942–1999
Jump to: 2023 | 2022 | 2021 | 2020



Doherty N, Cardwell C, Murchie P, Hill C, Azoulay L, Hicks B. Use of 5-alpha reductase inhibitors and risk of gastrointestinal cancers in men with benign prostatic hyperplasia: a population-based cohort study. Int J Cancer. 2024. doi:10.1002/ijc.34937 • PubMed

Morote J, Picola N, Muñoz-Rodriguez J, et al. Effect of 5-alpha reductase inhibitors on magnetic resonance imaging and prostate cancer detection. Biomolecules. 2024. doi:10.3390/biom14020193PubMed • PMC full text

Pyun JH, Son NH, Ko YH, Kim SW, Kim H, Bae YJ. The long-term impact of 5-alpha reductase inhibitors on the development of bladder cancer and the need for radical cystectomy: a nationwide observational study. World J Mens Health. 2024. doi:10.5534/wjmh.230137 • PubMed

📚 Wang Y, Song Y, Peng Y, et al. Effects of androgen suppression therapy on the incidence and prognosis of bladder cancer: an updated systematic review and meta-analysis. Urol Oncol. 2024. doi:10.1016/j.urolonc.2024.04.014 • PubMed

Yang DY, Seo WW, Park RW, et al. Comparison of finasteride and dutasteride on risk of prostate cancer in patients with benign prostatic hyperplasia: a pooled analysis of 15 real-world databases. World J Mens Health. 2024. doi:10.5534/wjmh.230327 • PubMed


💊 [Some authors are employees of Wellster Healthtech Group which operates telehealth services] Abeck F, Hansen I, Kött J, et al. Patient-reported outcomes of topical finasteride/minoxidil treatment for male androgenetic alopecia: a retrospective study using telemedical data. J Cosmet Dermatol. 2024. doi:10.1111/jocd.16360 • PubMed

Choi S, Kwon SH, Sim WY, Lew BL. Long-term efficacy and safety of dutasteride 0.5 mg in Korean men with androgenetic alopecia: 5-year data demonstrating clinical improvement with sustained efficacy. J Dermatol. 2024. doi:10.1111/1346-8138.17138 • PubMed

Gupta AK, Talukder M, Williams G. Emerging and traditional 5-α reductase inhibitors and androgen receptor antagonists for male androgenetic alopecia. Expert Opin Emerg Drugs. 2024. doi:10.1080/14728214.2024.2346590 • PubMed

Panchaprateep R. Medical treatment for androgenetic alopecia. Facial Plast Surg. 2024. doi:10.1055/a-2196-4713PubMed

Rosenthal A, Conde G, Greco JF, Gharavi NM. Management of androgenic alopecia: a systematic review of the literature. J Cosmet Laser Ther. 2024. doi:10.1080/14764172.2024.2362126 • PubMed


Farkas HS, Jee YH, Szymczuk V, Leschek EW. Persistent gynecomastia due to short-term low-dose finasteride for androgenetic alopecia. JCEM Case Rep. 2024. doi:10.1210/jcemcr/luae050 • PubMed • PMC full text

Ziogou A, Giannakodimos A, Mitakidi E, Konstantinos T, Giannakodimos I. Is there an association between 5a reductase inhibitors and metabolic syndrome? A narrative review of the literature. Rev Recent Clin Trials. 2024. doi:10.2174/0115748871303638240529160610 • PubMed

Environmental toxicology

Cho H, Sung SE, Jang G, et al. Adverse effects of the 5-alpha-reductase inhibitor finasteride on Daphnia magna: endocrine system and lipid metabolism disruption. Ecotoxicol Environ Saf. 2024. doi:10.1016/j.ecoenv.2024.116606 • PubMed

Neuroendocrinology & neuropsychiatry

🐀 🧬 Giatti S, Cioffi L, Diviccaro S, Piazza R, Melcangi RC. Analysis of the finasteride treatment and its withdrawal in the rat hypothalamus and hippocampus at whole-transcriptome level. J Endocrinol Invest. 2024. doi:10.1007/s40618-024-02345-y • PubMed

Giatti S, Diviccaro S, Cioffi L, Melcangi RC. Post-finasteride syndrome and post-SSRI sexual dysfunction: two clinical conditions apparently distant, but very close. Front Neuroendocrinol. 2024. doi:10.1016/j.yfrne.2023.101114 • PubMed

🐀 Sasibhushana RB, Shankaranarayana Rao BS, Srikumar BN. Anxiety-, and depression-like behavior following short-term finasteride administration is associated with impaired synaptic plasticity and cognitive behavior in male rats. J Psychiatr Res. 2024. doi:10.1016/j.jpsychires.2024.04.029 • PubMed


Gaddameedi SR, Khan MA, Arty F, et al. An unusual case of thalamic stroke in a young adult with patent foramen ovale and finasteride use. Cureus. 2024. doi:10.7759/cureus.60300 • PubMedPMC full text


Ratra D, Lakshmipathy B, Ratra V. Finasteride-associated central retinal vein occlusion. Clin Exp Optom. 2024. doi:10.1080/08164622.2024.2349557 • PubMed

Pharmacovigilance & pharmacoepidemiology

Asanad K, Sholklapper T, Samplaski MK, Cacciamani GE. Global online interest in finasteride sexual side effects. Int J Impot Res. 2024. Epub 2022 Sep 13. doi:10.1038/s41443-022-00612-1PubMed

📚 Uleri A, Nicolas Cornu J, Gobbo A, et al. Association of 5α-reductase inhibitors with depression and suicide: a mini systematic review and meta-analysis. Eur Urol Focus. 2024. doi:10.1016/j.euf.2024.04.009 • PubMed

Nguyen DD, Bhojani N, Trinh QD. Re: Alessandro Uleri, Jean Nicolas Cornu, Andrea Gobbo, et al. Association of 5α-reductase Inhibitors with depression and suicide: a mini systematic review and meta-analysis. Original article in: Eur Urol Focus (doi:10.1016/j.euf.2024.04.009). Comment in: Eur Urol Focus. 2024. doi:10.1016/j.euf.2024.06.013 • PubMed

Nacchia A, Franco A, Cicione A, et al. Medications mostly associated with ejaculatory disorders: assessment of the EudraVigilance (EV) and Food and Drug Administration (FDA) pharmacovigilance databases entries. Urology. 2024. doi:10.1016/j.urology.2023.12.021 • PubMed

Pennap D, Mosholder AD, Ajao A, et al. Suicide and intentional self-harm among older men treated with 5-alpha reductase inhibitor or alpha-blockers for benign prostatic hyperplasia. Urology. 2024. doi:10.1016/j.urology.2024.06.013 • PubMed

Tan H, Luo L, Li W, et al. A pharmacovigilance study of drug-reduced male semen quality based on the Food and Drug Administration adverse event reporting system database. Andrology. 2024. doi:10.1111/andr.13668 • PubMed

See also: Medical & pharmaceutical industry news

Reproductive toxicology

🐀 Nabil I, Eid AA, Yassin HA, Abouelrous RA, Solaiman AA. Protective role of hesperidin in finasteride-induced testicular toxicity in adult male wistar rats: insights into oxidative stress, apoptosis, and ultrastructure of seminiferous tubules. Reprod Toxicol. 2024. doi:10.1016/j.reprotox.2024.108535 • PubMed

Urology & andrology

Abou-Farha M, Hagras A, Nagla S. Effect of dose reduction of dutasteride in combination with alpha-blockers in patients with lower urinary tract symptoms/benign prostatic enlargement. Urol Ann. 2024. doi:10.4103/ua.ua_15_22 • PubMed • PMC full text

Carson CC. Post-finasteride syndrome: real or myth? Trends in Urology & Men’s Health. 2024. doi:10.1002/tre.972

🐀 Diviccaro S, Herian M, Cioffi L, et al. Exploring rat corpus cavernosum alterations induced by finasteride treatment and withdrawal. Andrology. 2023. doi:10.1111/andr.13515 • PubMed

Kuliš I, Margan Koletić Ž, Hudolin T, Tomić S. Review of adverse drug reactions of medicines used for the treatment of benign prostatic hyperplasia reported to HALMED. Acta Clin Croat. 2023. doi:10.20471/acc.2023.62.s2.10 • PubMed • PMC full text

Lauck KC, Limmer A, Harris P, Kivelevitch D. Sexual dysfunction with 5-alpha-reductase inhibitor therapy for androgenetic alopecia: a global propensity score matched retrospective cohort study. J Am Acad Dermatol. 2024. doi:10.1016/j.jaad.2024.03.019 • PubMed

Perelman MA 💊 [Consultant for Merck’s law firm in Propecia litigation]. Comment on “The post-finasteride syndrome: possible etiological mechanisms and symptoms”. Int J Impot Res. 2024. doi:10.1038/s41443-024-00886-7 • PubMed. Correction published on 12 Apr 2024

See also: Tan et al. in Pharmacovigilance & pharmacoepidemiology

2024 abstracts

Peters KM, Stachelek JA, Zwaans BMM. NM 094 | Post-retinoid, post-finasteride and post-SSRI syndromes: patient evaluation and initial treatment. Poster presented at: SUFU 2024 Winter Meeting (Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction); February 20–24, 2024; Fort Lauderdale, FL. Abstract (p. 303 of program) • Tweet with poster image

🧬 Ihentuge CJ, Csoka AB. Epigenetic effects of finasteride on dopaminergic signaling pathways: a potential contributor to post-finasteride syndrome. Physiology. 2024 May 21;39(S1). doi:10.1152/physiol.2024.39.S1.1269


↑ back to top

2023 subsections: Cancer • Cardiology • Dermatology • Gastroenterology • Legal matters • NeuroendocrinologyPediatrics • Pharmacovigilance • Reproductive toxicology • Telehealth • Urology / andrology


An MH, Kim MS, Kim C, et al. Association of 5α-reductase inhibitor prescription with bladder cancer progression in males in South Korea. JAMA Netw Open. 2023. doi:10.1001/jamanetworkopen.2023.13667PubMed

📚 Baboudjian M, Gondran-Tellier B, Dariane C, et al. Association between 5α-reductase inhibitors and prostate cancer mortality: a systematic review and meta-analysis. JAMA Oncol. 2023. doi:10.1001/jamaoncol.2023.0260 • PubMed • PMCID: PMC10119773 (full text available 4/20/2024)

Dekalo S, McArthur E, Campbell J, Ordon M, Power N, Welk B. 5α-reductase inhibitors and the risk of bladder cancer in a large, population-based cohort. Urol Oncol. 2023. doi:10.1016/j.urolonc.2022.09.004PubMed

Del Giudice F, Belladelli F, Glover F, et al. 5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for benign prostatic hyperplasia do NOT lower the risk of incident bladder cancer: United States insurance claims data. World J Urol. 2023. doi:10.1007/s00345-023-04551-4PubMed

Doherty N, Cardwell CR, Murchie P, Hill C, Azoulay L, Hicks B. 5-alpha reductase inhibitors and risk of kidney and bladder cancers in men with benign prostatic hyperplasia: a population-based cohort study. Cancer Epidemiol Biomarkers Prev. 2023. doi:10.1158/1055-9965.EPI-22-1109 • PubMed

Falagario UG, Lantz A, Jambor I, et al; PROMOD Study Group. Diagnosis of prostate cancer with magnetic resonance imaging in men treated with 5-alpha-reductase inhibitors. World J Urol. 2023. doi:10.1007/s00345-023-04634-2 • PubMed

Rabbani S, Mattsson F, Lagergren J, Xie S. Use of 5α-reductase inhibitors and survival of oesophageal and gastric cancer in a nationwide Swedish cohort study. Acta Oncol. 2023. doi:10.1080/0284186X.2023.2214681PubMed

Seok J, Kwak HJ, Kwak Y, et al. Anti-oncogenic effects of dutasteride, a dual 5-alpha reductase inhibitor and a drug for benign prostate hyperplasia, in bladder cancer. J Transl Med. 2023. doi:10.1186/s12967-023-03972-4 • PubMed • PMC full text

Go to bibliography on cancer risk →


💊 [See Conflict of Interest Disclosures] Zhang J, Latour CD, Olawore O, et al. Cardiovascular outcomes of α-blockers vs 5-α reductase inhibitors for benign prostatic hyperplasia. JAMA Netw Open. 2023. doi:10.1001/jamanetworkopen.2023.43299 • PubMed • PMC full text

See also: In Pharmacovigilance & drug safety: Ayele et al, 2023


Courtney A, Triwongwarant D, Chim I, Eisman S, Sinclair R. Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia. Expert Opin Pharmacother. 2023. doi:10.1080/14656566.2023.2280630 • PubMed

Devjani S, Ezemma O, Kelley KJ, Stratton E, Senna M. Androgenetic alopecia: therapy update. Drugs. 2023. doi:10.1007/s40265-023-01880-x • PubMedPMC full text

Escamilla-Cruz M, Magaña M, Escandón-Perez S, Bello-Chavolla OY. Use of 5-alpha reductase inhibitors in dermatology: a narrative review. Dermatol Ther (Heidelb). 2023. doi:10.1007/s13555-023-00974-4 • PubMed

Irwig MS, Sanz J, Lin D, Tan N, Dommasch E. Beliefs and counseling practices among dermatologists regarding sexual and other adverse effects of finasteride. Int J Impot Res. 2023. doi:10.1038/s41443-023-00750-0 • PubMedOnline access via Springer Nature

Jia H, Ran L. Maculopapular drug eruption caused by finasteride: a case report. Clin Cosmet Investig Dermatol. 2023. doi:10.2147/CCID.S426747PubMedPMC full text

Kaiser M, Abdin R, Gaumond SI, Issa NT, Jimenez JJ. Treatment of androgenetic alopecia: current guidance and unmet needs. Clin Cosmet Investig Dermatol. 2023. doi:10.2147/CCID.S385861PubMedPMC full text

Ly NY, Fruechte S, Hordinsky MK, Sadick N, Arruda S, Farah RS. Medical and procedural treatment of androgenetic alopecia – Where are we? J Am Acad Dermatol. 2023. doi:10.1016/j.jaad.2023.05.004PubMed

Muddebihal A, Khurana A, Kulhari A, Ahuja A. Psoriasiform drug eruption to finasteride: uncommon side effect of a commonly used drug. Int J Trichology. 2022. doi:10.4103/ijt.ijt_42_21PubMedPMC full text

📚 Nobari NN, Roohaninasab M, Sadeghzadeh-Bazargan A, et al. A systematic review of clinical trials using single or combination therapy of oral or topical finasteride for women in reproductive age and postmenopausal women with hormonal and nonhormonal androgenetic alopecia. Adv Clin Exp Med. 2023. doi:10.17219/acem/157990PubMed


Yance S, Montes P. Hepatotoxicidad por tamsulosina / dutasterida: reporte de un caso probable [Hepatotoxicity by tamsulosin / dutasteride: report of a probable case]. Rev Gastroenterol Peru. 2023. Spanish. doi:10.47892/rgp.2023.433.1544English translation (PDF)PubMed

Nguyen DD, Fellouah M, Nguyen AV, et al. Litigation associated with 5-alpha-reductase-inhibitor use: a Canadian legal database review. Can J Urol. 2023. Via journal site • PubMed

Go to bibliography on legal matters →


Walton NL, Antonoudiou P, Maguire JL. Neurosteroid influence on affective tone. Neurosci Biobehav Rev. 2023. doi:10.1016/j.neubiorev.2023.105327PubMed

See also: In Urology & andrology: Diviccaro et al, 2023


Levy B, Teplitsky S, Kalaitzoglou E, Kahler S, Matheny JP, Saltzman AF. “Exogenous” 5 alpha reductase deficiency: a case report. Urology. 2023. doi:10.1016/j.urology.2023.05.001 • PubMed

Pharmacovigilance & drug safety

Ayele HT, Reynier P, Azoulay L, et al. The cardiovascular safety of 5-alpha-reductase inhibitors among men with benign prostatic hyperplasia: a population-based cohort study. Am J Med. 2023. doi:10.1016/j.amjmed.2023.06.021PubMed

Baldini S, Khattak A, Capogrosso P, et al. The possible role of prescribing medications, including central nervous system drugs, in contributing to male-factor infertility (MFI): assessment of the Food and Drug Administration (FDA) pharmacovigilance database. Brain Sci. 2023. doi:10.3390/brainsci13121652 • PubMed • PMC full text

Brezis M. Neuropsychiatric reactions to finasteride: nocebo or true effect? J Basic Clin Pharma. 2023;14(1):220-222. Web • PDF

Cho Y, Bea S, Bae JH, Kim DH, Lee JH, Shin JY. Cognitive dysfunction following finasteride use: a disproportionality analysis of the global pharmacovigilance database. Expert Opin Drug Saf. 2023. doi:10.1080/14740338.2023.2294926 • PubMed

Fusaroli M, Simonsen A, Borrie SA, et al. Identifying medications underlying communication atypicalities in psychotic and affective disorders: a pharmacovigilance study within the FDA Adverse Event Reporting System. J Speech Lang Hear Res. 2023. doi:10.1044/2023_JSLHR-22-00739PubMed

Laanani M, Weill A, Jollant F, Zureik M, Dray-Spira R. Suicidal risk associated with finasteride versus dutasteride among men treated for benign prostatic hyperplasia: nationwide cohort study. Sci Rep. 2023. doi:10.1038/s41598-023-32356-3PubMedPMC full text

Müderrisoglu AE, de la Rosette JJMCH, Michel MC. Potential side effects of currently available pharmacotherapies in male lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Expert Opin Drug Saf. 2023. doi:10.1080/14740338.2023.2293206PubMed

Nguyen DD, Herzog P, Cone EB, et al. Disproportional signal of sexual dysfunction reports associated with finasteride use in young men with androgenetic alopecia: a pharmacovigilance analysis of VigiBase. J Am Acad Dermatol. 2023. doi:10.1016/j.jaad.2022.03.037PubMed

Schifano N, Capogrosso P, Boeri L, et al. Are finasteride-related penile curvature/Peyronie’s disease adverse event reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases. Int J Impot Res. 2023. doi:10.1038/s41443-022-00568-2 • PubMed

See also: In Dermatology: Irwig et al, 2023.

Reproductive toxicology

📚 Santana FFV, Lozi AA, Gonçalves RV, Da Silva J, Da Matta SLP. Comparative effects of finasteride and minoxidil on the male reproductive organs: a systematic review of in vitro and in vivo evidence. Toxicol Appl Pharmacol. 2023. doi:10.1016/j.taap.2023.116710 • PubMed


💊 [Two authors are employees of Wellster Healthtech Group; more details in Disclosure] Abeck F, Hansen I, Wiesenhütter I, et al. Online traffic analysis of direct-to-consumer websites for hair loss treatment and characterization of finasteride patients on a platform in Germany: a potential paradigm shift in the treatment of androgenetic alopecia. Clin Cosmet Investig Dermatol. 2023. doi:10.2147/CCID.S400614 • PubMedPMC full text

💊 [Three authors are employees of Wellster Healthtech Group; more details in Footnotes] von Büren J, Hansen I, Kött J, et al. Patient-reported treatment outcomes and safety of direct-to-consumer teledermatology for finasteride treatment in male androgenetic alopecia: a cross-sectional study. Digit Health. 2023. doi:10.1177/20552076231205740 • PubMedPMC full text

Urology & andrology

Al Saffar H, Xu J, O’Brien JS, Kelly BD, Murphy DG, Lawrentschuk N. US Food and Drug Administration warning regarding finasteride and suicidal ideation: What should urologists know? Eur Urol Open Sci. 2023. doi:10.1016/j.euros.2023.04.009 • PubMed • PMC full text

Bilhim T. Do we still need 5α-reductase inhibitors for patients with benign prostatic hyperplasia after the PARTEM study? Cardiovasc Intervent Radiol. 2023. doi:10.1007/s00270-023-03526-7PubMed

Chislett B, Chen D, Perera ML, Chung E, Bolton D, Qu LG. 5-alpha reductase inhibitors use in prostatic disease and beyond. Transl Androl Urol. 2023. doi:10.21037/tau-22-690PubMedPMC full text

🐀 Da Silva MHA, Costa WS, Sampaio FJB, de Souza DB. Effects of dutasteride and tamsulosin on penile morphology in a rodent model. Int Braz J Urol. 2023. doi:10.1590/S1677-5538.IBJU.2022.0583Full text (PDF)PubMed

Gül M, Fode M, Urkmez A, et al. A clinical guide to rare male sexual disorders. Nat Rev Urol. 2023. doi:10.1038/s41585-023-00803-5 • PubMed

Leliefeld HHJ, Debruyne FMJ & Reisman Y. The post-finasteride syndrome: possible etiological mechanisms and symptoms. Int J Impot Res. 2023. doi:10.1038/s41443-023-00759-5PubMed

🐀 Marghani BH, Ezz MA, Ateya AI, Fehaid A, Saleh RM, Rezk S. Comparative effects of finasteride and laser-irradiated silver nanoparticles on testicular function and histology in testosterone induced benign prostatic hyperplasia in rats. Life Sci. 2023. doi:10.1016/j.lfs.2023.121747PubMed

Sapoval M, Thiounn N, Descazeaud A, et al; PARTEM study group. Prostatic artery embolisation versus medical treatment in patients with benign prostatic hyperplasia (PARTEM): a randomised, multicentre, open-label, phase 3, superiority trial. Lancet Reg Health Eur. 2023. doi:10.1016/j.lanepe.2023.100672PubMedPMC full text

Taniguchi H, Inoue T, Kawa G, et al. Evaluation of sexual function after dutasteride treatment in patients with once-negative prostate biopsy and benign prostate hyperplasia. Urologia Journal. 2023. doi:10.1177/03915603231163201PubMed

See also: In Cancer: Baboudjian et al, 2023. In Pediatrics: Levy et al, 2023.

2023 abstracts

Deveci S, Sullivan JF, Tal R, Mulhall JP. (122) Erectile hemodynamics asessment in ED patients with self-diagnosed post-finasteride syndrome (PFS). J Sex Med. 2023. doi:10.1093/jsxmed/qdad060.117


↑ back to top


Björnebo L, Nordström T, Discacciati A, et al. Association of 5α-reductase inhibitors with prostate cancer mortality. JAMA Oncol. 2022 Jul 1. doi:10.1001/jamaoncol.2022.1501. Erratum in: JAMA Oncol. 2022 Jun 16. PubMed

Garg H, Wheeler KM, Dursun F, et al. Impact of finasteride on survival in bladder cancer: a retrospective multi-institutional database analysis. Clin Genitourin Cancer. 2022 Oct. doi:10.1016/j.clgc.2022.10.014PubMed

Rabbani S, Santoni G, Lagergren J, Xie SH. Use of anti-androgenic 5α-reductase inhibitors and risk of oesophageal and gastric cancer by histological type and anatomical sub-site. Br J Cancer. 2022 Jun 17. doi:10.1038/s41416-022-01872-wPubMed

Go to bibliography on cancer risk →


💊 [Funded by GSK] Choi GS, Sim WY, Kang H, et al. Long-term effectiveness and safety of dutasteride versus finasteride in patients with male androgenic alopecia in South Korea: a multicentre chart review study. Ann Dermatol. 2022 Oct. doi:10.5021/ad.22.027PubMed

🐀 da Cruz GK, Martins MIM, Antunes FTT, et al. Evaluation of the efficacy and toxicity of oral and topical pumpkin oil on the hair growth of mice. Acta Histochem. 2022 Apr 18. doi:10.1016/j.acthis.2022.151894PubMed [Includes finasteride treatment group]

Gupta AK, Talukder M. Topical finasteride for male and female pattern hair loss: Is it a safe and effective alternative? J Cosmet Dermatol. 2022 May. doi:10.1111/jocd.14895PubMed

Gupta AK, Talukder M, Williams G. Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia. J Dermatolog Treat. 2022 Aug 3. doi:10.1080/09546634.2022.2109567PubMed

Huang KP, Senna MM. Hair are the rankings—5-α reductase inhibitors and minoxidil in male androgenetic alopecia. JAMA Dermatol. 2022 Feb 2. doi:10.1001/jamadermatol.2021.5625PubMed

Melo DF, Saceda-Corralo D, Tosti A 💊 [COIs], et al. Frontal edema due to mesotherapy for androgenetic alopecia: a case series. Dermatol Ther. 2022 Feb. doi:10.1111/dth.15247 • PubMed

💊 [Funded by Polichem & Almirall] Piraccini BM, Blume-Peytavi U, Scarci F, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2022. doi:10.1111/jdv.17738. Erratum in: J Eur Acad Dermatol Venereol. 2023. PubMedPMC full text

Reguero Del Cura L, De Quintana Sancho A, Rubio Lombraña M, López Sundh AE, González López MA. Two cases of paradoxical nonscarring alopecia after mesotherapy with dutasteride. Skin Appendage Disord. 2022 Jan. doi:10.1159/000518043PubMed

Sand J, Walen S. Noninvasive hair rejuvenation. Facial Plast Surg Clin North Am. 2022 Aug. doi:10.1016/j.fsc.2022.03.015PubMed

Trüeb RM, Luu NC, Gavazzoni Dias MFR, Dutra Rezende H. How to deal with the issues of fertility, malignancies, and the postfinasteride syndrome while prescribing finasteride for male pattern hair loss. Skin Appendage Disord. 2022 May. doi:10.1159/000520493 • PubMed

Yanagisawa M, Sato A. Long-term (over 10 years) evaluation of efficacy and safety of finasteride in Japanese men with androgenetic alopecia: summary of three investigations. Hair Transplant Forum International. 2022 Jul;32(4):130-132. doi:10.33589/32.4.130.

See also: In Urology & sexual medicine: Hui et al, 2022. In Post-finasteride syndrome: Trüeb 2022.


Rzeszotek S, Kolasa A, Pilutin A, Misiakiewicz-Has K, Sielatycka K, Wiszniewska B. The interplay between finasteride-induced androgen imbalance, endoplasmic reticulum stress, oxidative stress, and liver disorders in paternal and filial generation. Biomedicines. 2022. doi:10.3390/biomedicines10112725

Go to bibliography: effects on liver, pancreas, metabolism, diabetes & kidneys →

Metabolomics & genomics

🧬 Surendran P, Stewart ID, Au Yeung VPW, et al. Rare and common genetic determinants of metabolic individuality and their effects on human health. Nat Med. 2022. doi:10.1038/s41591-022-02046-0 • PubMed • PMC full text

Neuroendocrinology & neuropharmacology

🐀 Dhillon HK, Singh T, Goel RK. Ferulic acid inhibits catamenial epilepsy through modulation of female hormones. Metab Brain Dis. 2022 Aug 6. doi:10.1007/s11011-022-01054-w • PubMed [Finasteride increased seizure susceptibility and depression-like characteristics]

🐀 Diviccaro S, Giatti S, Cioffi L, et al. Gut inflammation induced by finasteride withdrawal: therapeutic effect of allopregnanolone in adult male rats. Biomolecules. 2022. doi:10.3390/biom12111567 • Link via journal

Ocular effects

Calvao J, Feijão J, Soares RO. Finasteride and floppy iris syndrome: What role can the dermatologist play? [Letter]. Int J Trichology. 2022 May-Jun. doi:10.4103/ijt.ijt_118_20PubMedPMC full text

📚 Christou CD, Esagian SM, Ziakas N, Prousali E, Tzamalis A. Factors predisposing to intraoperative floppy iris syndrome (IFIS): an updated systematic review and meta-analysis. J Cataract Refract Surg. 2022 Jul 20. doi:10.1097/j.jcrs.0000000000001017PubMed

Go to bibliography: effects on eyes & visual function →

Pharmacovigilance & drug safety

Garcia-Argibay M, Hiyoshi A, Fall K, Montgomery S. Association of 5α-reductase inhibitors with dementia, depression, and suicide. JAMA Netw Open. 2022. doi:10.1001/jamanetworkopen.2022.48135PubMed

Kaplan-Marans E, Sandozi A, Martinez M, Lee J, Schulman A, Khurgin J. Medications most commonly associated with erectile dysfunction: evaluation of the Food and Drug Administration national pharmacovigilance database. Sex Med. 2022. doi:10.1016/j.esxm.2022.100543 (full text available) • PubMed

Yeon B, Suh AY, Choi E, et al. Depression risk associated with the use of 5α-reductase inhibitors versus α-blockers: a retrospective cohort study in South Korea. PLoS One. 2022 Mar 16. doi:10.1371/journal.pone.0265169PubMedPMC full text

📚 Zhang JJ, Shi X, Wu T, et al. Sexual, physical, and overall adverse effects in patients treated with 5α-reductase inhibitors: a systematic review and meta-analysis. Asian J Androl. 2022 Jul-Aug. doi:10.4103/aja202171PubMed

See also: In Urology & sexual medicine: Hui et al, 2022. In Post-finasteride syndrome: Irwig, 2022.

Post-finasteride syndrome

Alhetheli GI, Alrashidi FH, Alhammad SH. Post-finasteride syndrome: current views and where do we stand?. Ann Med Health Sci Res. 2022 Jan 24. doi:10.54608/annalsmedical.2022.23 • Full text at journal siteVia

Fierro MC, Yafi FA, Reisman Y. Post-Finasteride Syndrome. In: Reisman Y, Lowenstein L, Tripodi F, eds. Textbook of Rare Sexual Medicine Conditions. Cham: Springer; 2022: 65–79. doi:10.1007/978-3-030-98263-8_6

Irwig MS. How routine pharmacovigilance failed to identify finasteride’s persistent sexual side effects. Andrology. 2022. doi:10.1111/andr.13122PubMed

🧬 Li X, Guo Y, Lu Y, et al. Case report: a study of the clinical characteristics and genetic variants of post-finasteride syndrome patients. Transl Androl Urol. 2022 Oct. doi:10.21037/tau-22-92 • PubMedPMC full text

Romero Pérez P. Post-finasteride syndrome. Literature review. Arch Esp Urol. 2022 Jun. doi:10.56434/j.arch.esp.urol.20227505.56PubMed

Trüeb RM. Psychiatric comorbidity related to the therapy of male androgenetic alopecia independent of the 5-alpha reductase pathway. Skin Appendage Disord. 2022. doi:10.1159/000518750 • PubMed • PMC full text

See also: In Dermatology: Trüeb et al, 2022. In Pharmacovigilance & drug safety: Schifano et al, 2022; and Zhang et al, 2022.

Go to bibliography on lasting, multi-system dysfunctions →

Urology & sexual medicine

🐀 Flores RB, Angrimani DSR, Brito MM, et al. Frozen-thawed sperm analysis of benign prostatic hyperplasia dogs treated with finasteride. Front Vet Sci. 2022 Jun 30. doi:10.3389/fvets.2022.901943 • PubMedPMC full text

Hui EX, Huang X, Oon HH. Review of dermatologic medications and impact on male fertility, sexual dysfunction and teratogenicity. Andrology. 2022 Oct. doi:10.1111/andr.13236 • PubMed

📚 Li Y, Ma J, Qin XH, Hu CY. The efficacy and safety of dutasteride and finasteride in patients with benign prostatic hyperplasia: a systematic review and meta-analysis. Transl Androl Urol. 2022 Mar. doi:10.21037/tau-22-58PubMedPMC full text

Michel MC, Madersbacher S. Medikamentöse Behandlung des benignen Prostatasyndroms: Was gibt’s Neues? [Medical treatment of male lower urinary tract symptoms: What’s new?]. Akt Urol. 2022;53:240–245. German. doi:10.1055/a-1749-4556 [Mentions post-5ARI syndrome]

💊 [Funded by NeoTract/Teleflex, seller of UroLift System] Roehrborn CG 💊 [COIs], Rukstalis DB. Prostatic urethral lift versus medical therapy: examining the impact on sexual function in men with benign prostatic hyperplasia. Eur Urol Focus. 2022 Jan. doi:10.1016/j.euf.2020.12.013PubMed

🐀 Yilmaz-Oral D, Onder A, Kaya-Sezginer E, Oztekin CV, Zor M, Gur S. Restorative effects of red onion (Allium cepa L.) juice on erectile function after-treatment with 5α-reductase inhibitor in rats. Int J Impot Res. 2022 Apr. doi:10.1038/s41443-021-00421-y • PubMed

2022 abstracts & preprints

Brezis M. Neuropsychiatric reactions to finasteride: nocebo or true effect? Authorea. 2022 Aug 10. doi:10.22541/au.166012115.57216742/v1

Campbell K, Velazquez O, Sullivan J, Lipshultz L. Finasteride-associated suicide and depression in men treated for hypogonadism and impotence. J Sex Med. 2022;19(4):S4-S5. doi:10.1016/j.jsxm.2022.01.019Abstract with chart (PDF)2021 poster • See also video interview in Grey literature: Presentations & webinars

Carlisle M, Uloko M, Yee A, Goldstein S, Goldstein I. Vascular, neurologic and hormonal abnormalities in men with persistent sexual dysfunction after discontinuation of finasteride. J Urol. 2022 May 1;207(5S):e620–621. doi:10.1097/JU.0000000000002592.07Poster (PDF)

Fusaroli M, Simonsen A, Borrie SA, et al. Identifying medications underlying communication atypicalities in psychotic and affective disorders: a pharmacovigilance study within the FDA Adverse Event Reporting System. medRxiv. Published online 2022. doi:10.1101/2022.09.05.22279609

🐀 Giatti S, Diviccaro S, Di Domizio A, et al. Finasteride inhibits epinephrine synthesis in humans: implication for sexual dysfunction. Endocrine Abstracts. 2022 May;81:P448. doi:10.1530/endoabs.81.P448

🧬 Ihentuge C, Csoka A. Finasteride induces epigenetic modulation of LSP1: a gene implicated in neutrophil actin dysfunction disease. FASEB J. 2022 May;36 Suppl 1. doi:10.1096/fasebj.2022.36.S1.R4708

Kaplan-Marans E, Martinez M, Sandozi A, Lee J, Khurgin J, Schulman A. PD49-02 Medications most commonly associated with erectile dysfunction: evaluation of the Food and Drug Administration national pharmacovigilance database. J Urol. 2022 May;207 Suppl 5:e830. doi:10.1097/JU.0000000000002620.02 [See paper in Sex Med above]

Nguyen BJ, Meer E, Gupta AS, et al. The effect of finasteride on dry eye disease. Paper presented at: ARVO 2022: Annual Meeting of the Association for Research in Vision and Ophthalmology; May 1, 2022; Denver, CO. Abstract (PDF)

Nguyen D, Herzog P, Cone EB, et al. Pharmacovigilance analysis of reports of sexual dysfunction associated with finasteride use: implications for the post-finasteride syndrome. J Sex Med. 2022;19(5, Supplement 2):S130-S131. doi:10.1016/j.jsxm.2022.03.553 • Direct link on journal website

Nguyen DD, Herzog P, Cone EB, et al. Pharmacovigilance analysis of reports of sexual dysfunction associated with finasteride use: implications for the post-finasteride syndrome (342494). Poster presented at: 41st Congress of the Société Internationale d’Urologie / SIU Academy; November 12, 2021; Dubai, United Arab Emirates. Poster

Wesley D, Bronsther R. (135) Post-finasteride syndrome: a case presentation and discussion. Journal of the Academy of Consultation-Liaison Psychiatry. 2022;63(Suppl 2):S179. doi:10.1016/j.jaclp.2022.10.137Poster via conference site


↑ back to top


Gao JL, Streed CG Jr, Thompson J, Dommasch ED, Peebles JK. Androgenetic alopecia in transgender and gender diverse populations: a review of therapeutics. J Am Acad Dermatol. 2021 Oct. doi:10.1016/j.jaad.2021.08.067PubMed

Gupta AK, Venkataraman M, Talukder M, Bamimore MA. Finasteride for hair loss: a review. J Dermatolog Treat. 2021 Jul 22. doi:10.1080/09546634.2021.1959506 • PubMed

Kang MJ, Choi JY, Sim WY, Lew BL. 5α-reductase inhibitors in men aged 50 years or older with androgenetic alopecia: a retrospective study. J Am Acad Dermatol. 2021 Jan. doi:10.1016/j.jaad.2020.04.051PubMed

Nestor MS, Ablon G, Gade A, Han H, Fischer DL. Treatment options for androgenetic alopecia: efficacy, side effects, compliance, financial considerations, and ethics. J Cosmet Dermatol. 2021 Nov 6. doi:10.1111/jocd.14537PubMed

Rokni GR, Mohammadnezhad F, Saeedi M, et al. Efficacy, tolerability, and safety of montelukast versus finasteride for the treatment of moderate acne in women: A prospective, randomized, single-blinded, active-controlled trial. J Cosmet Dermatol. 2021 Oct 14. doi:10.1111/jocd.14462PubMed

Sattur SS, Sattur IS. Pharmacological management of pattern hair loss. Indian J Plast Surg. 2021 Dec. doi:10.1055/s-0041-1739254PubMedPMC full text

Trüeb RM. Understanding pattern hair loss—hair biology impacted by genes, androgens, prostaglandins and epigenetic factors. Indian J Plast Surg. 2021 Dec. doi:10.1055/s-0041-1739252PubMedPMC full text

Yamada T. Photosensitivity reaction induced by finasteride. J Gen Fam Med. 2021 Nov 5. doi:10.1002/jgf2.510PubMedPMC full text

Legal matters

Low P, Li KD, Hakam N, et al. 5-alpha reductase inhibitor related litigation: a legal database review. Andrology. 2021 Dec 21. doi:10.1111/andr.13145PubMed

Go to bibliography on legal matters →


Borgo F, Macandog AD, Diviccaro S, et al. Alterations of gut microbiota composition in post-finasteride patients: a pilot study. J Endocrinol Invest. 2021 Jun. doi:10.1007/s40618-020-01424-0PubMed • PMC full text


🐀 Da Silva MHA, Estrada JHD, Gregório BM, et al. Does treatment with dutasteride or finasteride has [sic] impact on renal morphology? Experimental study. Acta Cir Bras. 2021 Sep 15. doi:10.1590/ACB360703PubMedPMC full text

Go to bibliography: effects on liver, pancreas, metabolism, diabetes & kidneys →

Pharmacology & neuroendocrinology

🐀 Ahire A, Nair, KP, Shankaranarayana Rao BS, Srikumar BN. The potential involvement of cholinergic system in finasteride induced cognitive dysfunction. Psychoneuroendocrinology. 2021 Feb. doi:10.1016/j.psyneuen.2020.105066PubMed

Favilla V, Cannarella R, Trovato F, et al. Effects of dutasteride on sex hormones and cerebrospinal steroids in patients treated for benign prostatic hyperplasia. Endocrine. 2021 Sep. doi:10.1007/s12020-021-02675-4PubMed

Giatti S, Di Domizio A, Diviccaro S, et al. Three-dimensional proteome-wide scale screening for the 5-alpha reductase inhibitor finasteride: identification of a novel off-target. J Med Chem. 2021 Apr 22. doi:10.1021/acs.jmedchem.0c02039PubMedPMC full text

Saengmearnuparp T, Lojanapiwat B, Chattipakorn N, Chattipakorn S. The connection of 5-alpha reductase inhibitors to the development of depression. Biomed Pharmacother. 2021 Aug 31. doi:10.1016/j.biopha.2021.112100PubMedFull text via ScienceDirect

🧬 Villapalos-García G, Zubiaur P, et al. Effects of cytochrome P450 and transporter polymorphisms on the bioavailability and safety of dutasteride and tamsulosin. Front Pharmacol. 2021 Oct 7. doi:10.3389/fphar.2021.718281PubMedPMC full text

Pharmacovigilance & drug safety

Ayodele O, Cabral HJ, McManus D, Jick S. The risk of venous thromboembolism (VTE) in men with benign prostatic hyperplasia treated with 5-alpha reductase inhibitors (5ARIs). Clin Epidemiol. 2021 Aug 3. doi:10.2147/CLEP.S317019PubMedPMC full text

Bearelly P, Avellino GJ. The role of benign prostatic hyperplasia treatments in ejaculatory dysfunction. Fertil Steril. 2021 Sep. doi:10.1016/j.fertnstert.2021.07.1199PubMed

Gallo E, Maggini V, Lombardi N, et al. Serenoa repens induced erectile dysfunction: underdiagnosis and phytovigilance. Br J Clin Pharmacol. 2021 Nov 7. doi:10.1111/bcp.15129 • PubMed

Johnstone J, Lusty A, Tohidi M, et al. The association of new-onset diabetes mellitus and medical therapy for benign prostatic hyperplasia: a population-based study. Can Urol Assoc J. 2021 Aug. doi:10.5489/cuaj.7489PubMedPMC full text

La Torre A, Palleria C, Tamanini I, et al. Sexual dysfunctions related to drugs used in the management of lower urinary tract symptoms due to benign prostatic hyperplasia: a narrative review on α-blockers and 5-alpha reductase inhibitors. Uro. 2021. doi:10.3390/uro1030012

La Vignera S, Aversa A, Cannarella R, et al. Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects. Expert Opin Pharmacother. 2021 Feb. doi:10.1080/14656566.2020.1817382PubMed

Lulic Z, Son H, Yoo SB, et al. Free combination of dutasteride plus tamsulosin for the treatment of benign prostatic hyperplasia in South Korea: analysis of drug utilization and adverse events using the National Health Insurance Review and Assessment Service database. BMC Urol. 2021 Dec 21. doi:10.1186/s12894-021-00941-1PubMedPMC full text

Lusty A, Siemens DR, Tohidi M, Whitehead M, Tranmer J, Nickel JC. Cardiac failure associated with medical therapy of benign prostatic hyperplasia: a population based study. J Urol. 2021 Feb 22. doi:10.1097/JU.0000000000001561PubMed

📚 Pompili M, Magistri C, Maddalena S, Mellini C, Persechino S, Baldessarini RJ. Risk of depression associated with finasteride treatment. J Clin Psychopharmacol. 2021 May-Jun. doi:10.1097/JCP.0000000000001379PubMed

[Follow-up research letter] Baldessarini RJ, Pompili M. Further studies of effects of finasteride on mood and suicidal risk. J Clin Psychopharmacol. 2021 Nov-Dec 01. doi:10.1097/JCP.0000000000001485PubMed

Trüeb RM, Gavazzoni Dias MFR, Dutra Rezende H. Suicidality and psychological adverse events in patients treated with finasteride. Skin Appendage Disord. 2021. doi:10.1159/000514365 • PubMedPMC full text

Velez D, Ohlander S. Medical therapies causing iatrogenic male infertility. Fertil Steril. 2021 Sep. doi:10.1016/j.fertnstert.2021.07.1202PubMed

Post-finasteride syndrome

Healy D, Bahrick A, Bak M, et al. Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. Int J Risk Saf Med. 2021 Oct 26. doi:10.3233/JRS-210023 • PubMed • PMC full text

🧬 Howell S, Song W, Pastuszak A, Khera M. Differential gene expression in post-finasteride syndrome patients. J Sex Med. 2021 Sep. doi:10.1016/j.jsxm.2021.05.009PubMed

🐀 Oztekin CV, Yilmaz-Oral D, Kaya-Sezginer E, et al. Beneficial effects of human umbilical cord blood mononuclear cells on persistent erectile dysfunction after treatment of 5-alpha reductase inhibitor in rats. J Sex Med. 2021 May. doi:10.1016/j.jsxm.2021.02.005 • PubMed

Go to bibliography on lasting, multi-system dysfunctions →

Reproductive medicine

BinJadeed HF, Alajlan A. Pregnancy and neonatal outcome with maternal exposure to finasteride: case series. Journal of Dermatology and Dermatologic Surgery. 2021 Jul–Dec;25(2):84-86. doi:10.4103/jdds.jdds_33_21

Go to bibliography on teratogenicity →

Reproductive toxicology

Birch MR, Dissing S, Skakkebæk NE, Rehfeld A. Finasteride interferes with prostaglandin-induced CatSper-signalling in human sperm. Reproduction. 2021 Mar 1. doi:10.1530/REP-20-0287PubMed

🐀 🧬 Kolasa A, Rogińska D, Rzeszotek S, Machaliński B, Wiszniewska B. Paternal finasteride treatment can influence the testicular transcriptome profile of male offspring—preliminary study. Curr Issues Mol Biol. 2021 Jul 31. doi:10.3390/cimb43020062PubMed

🐀 🧬 Kur P, Kolasa-Wołosiuk A, Grabowska M, et al. The postnatal offspring of finasteride-treated male rats shows hyperglycaemia, elevated hepatic glycogen storage and altered GLUT2, IR, and AR expression in the liver. Int J Mol Sci. 2021 Jan 27. doi:10.3390/ijms22031242PubMedPMC full text

Go to bibliography on teratogenicity →

Urology & andrology

🐀 Lima CB, Angrimani DSR, Flores RB, Vannucchi CI. Endocrine, prostatic vascular, and proapoptotic changes in dogs with benign prostatic hyperplasia treated medically or surgically. Domest Anim Endocrinol. 2021 Apr. doi:10.1016/j.domaniend.2020.106601 • PubMed

Loughlin KR. The clinical applications of five-alpha reductase inhibitors. Can J Urol. 2021 Apr. PubMedFull text at journal site

2021 abstracts

Asanad K, Cacciamani GE, Samplaski MK. Consulting “Dr. Google” for finasteride sexual side effects: a contemporary worldwide trends analysis. Fertil Steril. 2021 Sep 1;Suppl 3. doi:10.1016/j.fertnstert.2021.07.912

De Nunzio C, Nacchia A, Lombardo R, et al. Sexual adverse events-related to dutasteride and finasteride: Analysis of real-life data from EudraVigilance database. Presented at 36th Annual EAU Congress (virtual). European Urology. 2021 Jun 1;Suppl 1. doi:10.1016/S0302-2838(21)00427-9

Nguyen DD, Herzog P, Cone EB, et al. Disproportional signal of sexual dysfunction reports associated with finasteride use in young men with androgenetic alopecia: pharmacovigilance analysis of VigiBase. Poster presented at: 22nd Annual Fall Meeting of SMSNA; October 21–24, 2021; Scottsdale, AZ.

Schifano N, Capogrosso P, Boeri L, et al. SC36 – Is finasteride intake associated with penile curvature/Peyronie’s Disease? Assessment of both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases. European Urology Open Science. 2021 Oct;32(Suppl 1);S18. doi:10.1016/S2666-1683(21)00727-8 • PDF at ScienceDirect. [See also Schifano et al, 2022 above]


↑ back to top


Kroumpouzos G. Effects of 5-alpha reductase inhibitors on lung function: a reason for discontinuation during COVID-19 pandemic?. Dermatol Ther. 2020. doi:10.1111/dth.13535 • PubMed


📚 Chen L, Zhang J, Wang L, Wang H, Chen B. The efficacy and safety of finasteride combined with topical minoxidil for androgenetic alopecia: a systematic review and meta-analysis. Aesthetic Plast Surg. 2020 Jun. doi:10.1007/s00266-020-01621-5PubMed

Dhurat R, Sharma A, Rudnicka L, et al. 5-alpha reductase inhibitors in androgenetic alopecia: shifting paradigms, current concepts, comparative efficacy, and safety. Dermatol Ther. 2020 May. doi:10.1111/dth.13379 • PubMed

Espasandín-Arias M, García-Rodiño S, Suárez-Peñaranda JM, Rodríguez-Granados MT. Photosensitivity associated with dutasteride therapy. J Dtsch Dermatol Ges. 2020 Apr. doi:10.1111/ddg.14062PubMed

📚 Herz-Ruelas ME, Álvarez-Villalobos NA, Millán-Alanís JM, et al. Efficacy of intralesional and oral dutasteride in the treatment of androgenetic alopecia: a systematic review. Skin Appendage Disord. 2020 Nov. doi:10.1159/000510697PubMed

Iamsumang W, Leerunyakul K, Suchonwanit P. Finasteride and its potential for the treatment of female pattern hair loss: evidence to date. Drug Des Devel Ther. 2020 Mar 2. doi:10.2147/DDDT.S240615PubMed

Motofei IG, Rowland DL, Tampa M, et al. Finasteride and androgenic alopecia; from therapeutic options to medical implications. J Dermatolog Treat. 2020. doi:10.1080/09546634.2019.1595507 • PubMed

Magdaleno-Tapial J, Valenzuela-Oñate C, García-Legaz-Martínez M, et al. Angioedema-like contact dermatitis caused by mesotherapy with dutasteride. Contact Dermatitis. 2020 Sep. doi:10.1111/cod.13585PubMed

Ruiz-Villaverde R, Ayen-Rodriguez A, Llamas-Molina JM. Quiz your knowledge: polycyclic annular plaques on the trunk following dutasteride treatment. Eur J Dermatol. 2020 Aug 1. doi:10.1684/ejd.2020.3823PubMed

Suchonwanit P, Iamsumang W, Leerunyakul K. Topical finasteride for the treatment of male androgenetic alopecia and female pattern hair loss: a review of the current literature. J Dermatolog Treat. 2020. doi:10.1080/09546634.2020.1782324 • PubMed

Vañó-Galván S, Saceda-Corralo D, Moreno-Arrones OM, et al. Effectiveness and safety of oral dutasteride for male androgenetic alopecia in real clinical practice: a descriptive monocentric study. Dermatol Ther. 2020 Jan. doi:10.1111/dth.13182PubMed

See also: Lehmann, 2020 in Legal matters.


🧬 Albasher G, Bin-Jumah M, Alfarraj S, et al. Prolonged use of finasteride-induced gonadal sex steroids alterations, DNA damage and menstrual bleeding in women. Biosci Rep. 2020. doi:10.1042/BSR20191434 • PubMed

Lee YR, Im E, Kim H, et al. Untargeted metabolomics and steroid signatures in urine of male pattern baldness patients after finasteride treatment for a year. Metabolites. 2020. doi:10.3390/metabo10040131 • PubMed

Othonos N, Marjot T, Woods C, et al. Co-administration of 5α-reductase inhibitors worsens the adverse metabolic effects of prescribed glucocorticoids. J Clin Endocrinol Metab. 2020 Sep 1. doi:10.1210/clinem/dgaa408PubMed

Traish AM. Health risks associated with long-term finasteride and dutasteride use: It’s time to sound the alarm. World J Mens Health. 2020 Jul. doi:10.5534/wjmh.200012 • PubMedPMC full text

[Letter] Sirufo MM, Ginaldi L, De Martinis M. Bone health risks associated with finasteride and dutasteride long-term use. World J Mens Health. 2020 Nov 26. 10.5534/wjmh.200138PubMed

Xu W, Schiffer L, Qadir MMF, et al. Intracrine testosterone activation in human pancreatic β-cells stimulates insulin secretion. Diabetes. 2020 Nov. doi:10.2337/db20-0228PubMedPMC full text

Environmental toxicology

🐀 Gilroy ÈAM, Bartlett AJ, Gillis PL, et al. Toxicity of the pharmaceuticals finasteride and melengestrol acetate to benthic invertebrates. Environ Sci Pollut Res Int. 2020. doi:10.1007/s11356-020-10121-7 • PubMed

Go to bibliography on environmental toxicology →

Legal matters

Lehmann P. [Post-finasteride-syndrome after prescription of 1 mg finasteride-tablet as a treatment for androgenetic hair loss]. Akt Dermatol. 2020. German; abstract in English. doi:10.1055/a-1023-3102

Höfner K. [Medical duty to warn in the case of post-finasteride syndrome]. Akt Urol. 2021. doi:10.1055/a-1257-8330

Go to bibliography on legal matters →


Choi BK, Cheon K, Cho BH, Jung JW, Lee KY. Cerebral venous sinus thrombosis associated with dutasteride use. Yonsei Med J. 2020 Jun. doi:10.3349/ymj.2020.61.6.553PubMedPMC full text

Neuropharmacology & neuroendocrinology

🐀 Bartolomé I, Llidó A, Darbra S, Pallarès M. Early postnatal neuroactive steroid manipulation differentially affects recognition memory and passive avoidance performance in male rats. Behav Brain Res. 2020. doi:10.1016/j.bbr.2020.112833 • PubMed

🐀 Mendell AL, Creighton SD, Wilson HA, et al. Inhibition of 5α reductase impairs cognitive performance, alters dendritic morphology and increases tau phosphorylation in the hippocampus of male 3xTg-AD mice. Neuroscience. 2020 Mar 1. doi:10.1016/j.neuroscience.2020.01.011 • PubMed


Fraunfelder, F. Chapter 7: Hormones and drugs affecting hormonal mechanisms. Drug-Induced Ocular Side Effects. 8th Edition. Elsevier; 2020.

Shin YK, Lee GW, Kang SW, Kim SJ, Kim AY. Macular abnormalities associated with 5α-reductase inhibitor. JAMA Ophthalmol. 2020 Jul 1. doi:10.1001/jamaophthalmol.2020.1279 • PubMed

[Letter] Burgos-Blasco B, Burgos-Blasco P. Macular abnormalities associated with 5α-reductase inhibitor. JAMA Ophthalmol. 2021 Feb 1. 10.1001/jamaophthalmol.2020.5768PubMed

[Reply] Shin YK, Kang SW. Macular abnormalities associated with 5α-reductase inhibitor-Reply. JAMA Ophthalmol. 2021 Feb 1. 10.1001/jamaophthalmol.2020.5774PubMed

Go to bibliography: effects on eyes & visual function →
Pharmacovigilance & drug safety

Bonde Miranda T, Garmo H, Stattin P, Robinson D. 5α-reductase inhibitors and risk of prostate cancer death. J Urol. 2020 Oct. doi:10.1097/JU.0000000000001038PubMed

📚 Deng T, Duan X, He Z, Zhao Z, Zeng G. Association between 5-alpha reductase inhibitor use and the risk of depression: a meta-analysis. Urol J. 2020 Aug 23. doi:10.22037/uj.v16i7.5866 • PubMed

Dyson TE, Cantrell MA, Lund BC. Lack of association between 5α-reductase inhibitors and depression. J Urol. 2020. doi:10.1097/JU.0000000000001079 • PubMed

Fang Q, Chen P, Du N, Nandakumar KS. Analysis of data from breast diseases treated with 5-alpha reductase inhibitors for benign prostatic hyperplasia. Clin Breast Cancer. 2019. doi:10.1016/j.clbc.2019.04.006 • PubMed

Gupta MA, Vujcic B, Gupta AK. Finasteride use is associated with higher odds of obstructive sleep apnea: results from the US Food and Drug Administration Adverse Events Reporting System. Skinmed. 2020. PubMed

Harrell MB, Ho K, Te AE, Kaplan SA 💊 [COIs], Chughtai B. An evaluation of the federal adverse events reporting system data on adverse effects of 5-alpha reductase inhibitors. World J Urol. 2020. doi:10.1007/s00345-020-03314-9 • PubMed

Ho RS. Ongoing concerns regarding finasteride for the treatment of male-pattern androgenetic alopecia. JAMA Dermatol. 2020 Nov 11. doi:10.1001/jamadermatol.2020.3384PubMed

Irwig MS. Finasteride and suicide: a postmarketing case series. Dermatology. 2020. doi:10.1159/000505151 • PubMed

Kim JA, Choi D, Choi S, Chang J, Park SM. The association of 5α-reductase inhibitor with suicidality. Psychosom Med. 2020 Apr. doi:10.1097/PSY.0000000000000784PubMed

📚 Kim JH, Shim SR, Khandwala Y, Del Giudice F, Sorensen S, Chung BI. Risk of depression after 5 alpha reductase inhibitor medication: meta-analysis. World J Mens Health. 2020 Oct. doi:10.5534/wjmh.190046 • PubMed

Kim YJ, Tae BS, Bae JH. Cognitive function and urologic medications for lower urinary tract symptoms. Int Neurourol J. 2020 Sep. doi:10.5213/inj.2040082.041 • PubMed

Kjærulff TM, Ersbøll AK, Pukkala E, et al. Characteristics of finasteride users in comparison with nonusers: A Nordic nationwide study based on individual-level data from Denmark, Finland, and Sweden. Pharmacoepidemiol Drug Saf. 2020. doi:10.1002/pds.4947 • PubMed

Nguyen DD, Marchese M, Cone EB, et al. Investigation of suicidality and psychological adverse events in patients treated with finasteride. JAMA Dermatol. 2020 Nov 11. doi:10.1001/jamadermatol.2020.3385PubMed

[Comment] Choi JW, Huh CH, Choi GS. Association of hair loss with suicidality and psychological adverse events vs finasteride use. JAMA Dermatol. 2021 Jun 1. doi:10.1001/jamadermatol.2021.1001PubMed

[Reply] Nguyen DD, Cone EB, Trinh QD. Association of hair loss with suicidality and psychological adverse events vs finasteride use-Reply. JAMA Dermatol. 2021 Jun 1. doi:10.1001/jamadermatol.2021.0377PubMed

📚 Wang L, Lei Y, Gao Y, Cui D, Tang Q, Li R, Wang D, Chen Y, Zhang B, Wang H. Association of finasteride with prostate cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2020 Apr. doi:10.1097/MD.0000000000019486 • PubMedPMC full text

See also: Post-finasteride syndrome; Albasher et al, 2020 in Endocrinology.

Post-finasteride syndrome

Frye CA, DaCosta D, Lembo VF, Walf AA. Advances in knowledge of androgens: how intentional and accidental neurosteroid changes inform us of their action and role.Curr Sex Health Rep. 2020;12:209–220. doi:10.1007/s11930-020-00276-2

Galushkin AA, Likhikh DG, Kogan MI. [Post-finasteride syndrome: our current knowledge]. Vestnik Urologii. 2020;8(2):50-54. Russian. doi:10.21886/2308-6424-2020-8-2-50-54 • Translation (PDF)

Kaur KK, Allahbadia G, Singh M. Post-finasteride syndrome – When will we get the courage to fight the dictating pharma industry – despite awareness of “sexual, neurological and metabolic side effects in young men for over a decade.” Arch Urol. 2020. doi:10.22259/2638-5228.0301003

Khera M, Than JK, Anaissie J, et al. Penile vascular abnormalities in young men with persistent side effects after finasteride use for the treatment of androgenic alopecia. Transl Androl Urol. 2020. doi:10.21037/tau.2020.03.21 • PubMedPMC full text

Moghalu O, Hotaling J, Pastuszak A. Psychiatric comorbidities and sexual health. Curr Sex Health Rep. 2020. doi:10.1007/s11930-020-00264-6

Pereira AFJR, Coelho TOA. Post-finasteride syndrome. Anais Brasileiros de Dermatologia. 2020 Mar 25. doi:10.1016/j.abd.2020.02.001 • PubMed

Traish AM. Post-finasteride syndrome: a surmountable challenge for clinicians. Fertil Steril. 2020. doi:10.1016/j.fertnstert.2019.11.030 • PubMed

See also: Lehmann, 2020 in Legal matters.

Go to bibliography on lasting, multi-system dysfunctions →

Urology & andrology

🐀 Angrimani DSR, Bicudo LC, Llamas Luceño N, et al. Does finasteride treatment for benign prostatic hyperplasia influence sperm DNA integrity in dogs?. Basic Clin Androl. 2020. doi:10.1186/s12610-020-00108-2 • PubMed

🐀 Angrimani DSR, Brito MM, Rui BR, Nichi M, Vannucchi CI. Reproductive and endocrinological effects of benign prostatic hyperplasia and finasteride therapy in dogs. Sci Rep. 2020. doi:10.1038/s41598-020-71691-7 • PubMed

🐀 Angrimani DSR, Francischini MCP, Brito MM, Vannucchi CI. Prostatic hyperplasia: vascularization, hemodynamic and hormonal analysis of dogs treated with finasteride or orchiectomy. PLoS One. 2020. doi:10.1371/journal.pone.0234714 • PubMed

📚 Busetto GM, Del Giudice F, D’Agostino D, et al. Efficacy and safety of finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: a critical review of the literature. Arch Ital Urol Androl. 2020. doi:10.4081/aiua.2019.4.205 • PubMed

🐀 Chen X, Feng H, El-Kott AF, Abd-Ella EM. Origanum vulgare L. leaves extract alleviates testis and sperm damages induced by finasteride: biochemical, immunohistological and apoptosis genes based evidences [sic]. Andrologia. 2020 Dec. doi:10.1111/and.13823 • PubMed

🐀 Da Silva MHA, Medeiros JL Jr, Costa WS, Sampaio FJB, De Souza DB. Effects of the dutasteride and sildenafil association in the penis of a benign prostatic hyperplasia animal model. Aging Male. 2020 Dec. doi:10.1080/13685538.2019.1653839PubMedJournal full text

🐀 Golchin-Rad K, Mogheiseh A, Nazifi S, Ahrari Khafi MS, Derakhshandeh N, Abbaszadeh-Hasiri M. Changes in the serum prostatic biomarkers during the treatment of benign prostatic hyperplasia with a 5alpha-reductase inhibitor: finasteride. Top Companion Anim Med. 2020. doi:10.1016/j.tcam.2020.100405 • PubMed

🐀 Gul A, Altinay S, Kabasakal L, Yavuz A, Semercioz A, Serefoglu EC. Effect of tadalafil on penile nitric oxide synthase and corporal smooth muscle in rats under dutasteride treatment. Aging Male. 2020 Jun. doi:10.1080/13685538.2020.1739019PubMed

Kuno T, Uchida Y, Usami T, et al. A young male of [sic] hemorrhagic cerebral infarction associated with finasteride and minoxidil. Nosotchu. 2020;42(4):244-247. Japanese. doi:10.3995/jstroke.10722 • ResearchGate • Automated translation to English (unofficial)

La Vignera S, Aversa A, Cannarella R, et al. Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects. Expert Opin Pharmacother. 2020. doi:10.1080/14656566.2020.1817382 • PubMed

🐀 Maldarine JS, Sanches BDA, Santos VA, et al. Postnatal exposure to finasteride causes different effects on the prostate of male and female gerbils. Cell Biol Int. 2020 Jun. doi:10.1002/cbin.11328PubMed

🐀 Mohebali S, Hayati Roodbari N, Hajihosseini R, Parivar K. The effects of finasteride on the expression of DAZL, TSGA10, SCYP3, PRM2 genes during spermatogenesis in testes of NMRI mice. Eur Rev Med Pharmacol Sci. 2020. doi:10.26355/eurrev_202008_22503 • PubMed

🐀 Olayinka ET, Adewole KE. In vivo and in silico evaluation of the ameliorative effect of hesperidin on finasteride-induced testicular oxidative stress in Wistar rats. Toxicol Mech Methods. 2020 Oct 1. doi:10.1080/15376516.2020.1831123 • PubMed

Pallotti F, Senofonte G, Pelloni M, et al. Androgenetic alopecia: effects of oral finasteride on hormone profile, reproduction and sexual function. Endocrine. 2020 Feb 12. doi:10.1007/s12020-020-02219-2 • PubMed

🐀 Shalaby AM, Alabiad MA, El Shaer DF. Resveratrol ameliorates the seminiferous tubules damages induced by finasteride in adult male rats. Microsc Microanal. 2020 Oct 5. doi:10.1017/S1431927620024514 • PubMed

📚 Zhou Z, Cui Y, Wu J, Jin H. Efficacy and safety of dutasteride compared with finasteride in treating males with benign prostatic hyperplasia: a meta-analysis of randomized controlled trials. Exp Ther Med. 2020. doi:10.3892/etm.2020.8851 • PubMed

2020 abstracts

🧬 Ihentuge C, Csoka A. Epigenetic effects of finasteride on human Leydig cells. The FASEB Journal. Supplement: Experimental Biology 2020 Meeting Abstracts. 2020;S1. doi:10.1096/fasebj.2020.34.s1.03823

Rivera Mirabal J, Than J, Annaisie J, et al. 124 The persistent effects of 5α-reductase inhibitors used in the treatment of androgenic alopecia on men’s health. J Sex Med. 2020;Suppl. doi:10.1016/j.jsxm.2019.11.070

Bibliographies: 2020–present | 2015–2019 | 2010–2014 | 2000–2009 | 1942–1999